Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
Rigel will mail the definitive proxy statement/prospectus to shareholders of record as of the close of business on January 10, 2025. Rigel will hold its Extraordinary General Meeting (the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback